Table 3.
Anticholinergic burden scales in predicting the presence of polypharmacy
| p value | OR | 95% CI for EXP (B) |
||
|---|---|---|---|---|
| lower | upper | |||
| Model 1 | ||||
| Disease duration | 0.201 | 1.112 | 0.945 | 1.307 |
| AP drug | 0.797 | 1.091 | 0.562 | 2.117 |
| ACB | 0.008 | 2.408 | 1.252 | 4.630 |
| Model 2 | ||||
| Disease duration | 0.129 | 1.131 | 0.965 | 1.325 |
| AP drug | 0.999 | 1.000 | 0.488 | 2.047 |
| ARS | 0.050 | 1.700 | 0.998 | 2.894 |
| Model 3 | ||||
| Disease duration | 0.068 | 1.158 | 0.989 | 1.357 |
| AP drug | 0.380 | 1.322 | 0.709 | 2.466 |
| ADS | 0.017 | 2.733 | 1.194 | 6.253 |
Nagelkerke R square for model 1, 0.345; Hosmer and Lemeshow test p = 0.475. Nagelkerke R square for model 2, 0.254; Hosmer and Lemeshow test p = 0.293. Nagelkerke R square for model 3, 0.319; Hosmer and Lemeshow test p = 0.506. ACB, Anticholinergic Cognitive Burden scale; ADS, Anticholinergic Drug Scale; ARS, Anticholinergic Risk Scale; AP, antiparkinson.